In general, the therapeutic effectiveness of anti‐HER2 and anti‐PD‐1 treatment is closely related to the amplification status of HER2 and combined positive score (CPS) for programmed death‐ligand 1 (PD‐L1) in the field of gastric cancer [14, 15]. This evidence concerns the gene ERBB2 and gastric cancer.